Sei Investments Co. grew its position in ChemoCentryx Inc (NASDAQ:CCXI) by 203.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,549 shares of the biopharmaceutical company’s stock after purchasing an additional 5,732 shares during the quarter. Sei Investments Co.’s holdings in ChemoCentryx were worth $113,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new position in ChemoCentryx during the 1st quarter worth $153,000. MetLife Investment Advisors LLC purchased a new stake in shares of ChemoCentryx in the first quarter valued at about $169,000. Barclays PLC boosted its holdings in shares of ChemoCentryx by 193.9% in the first quarter. Barclays PLC now owns 13,066 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 8,621 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of ChemoCentryx in the first quarter valued at about $196,000. Finally, Element Capital Management LLC purchased a new stake in shares of ChemoCentryx in the first quarter valued at about $197,000. Institutional investors and hedge funds own 54.43% of the company’s stock.
Several analysts have recently weighed in on CCXI shares. Raymond James started coverage on shares of ChemoCentryx in a report on Thursday, June 28th. They issued a “strong-buy” rating and a $18.00 target price on the stock. BidaskClub upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. Zacks Investment Research cut shares of ChemoCentryx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 3rd. ValuEngine cut shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $18.00 price objective on shares of ChemoCentryx in a research note on Friday, August 10th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. ChemoCentryx currently has an average rating of “Hold” and a consensus target price of $16.58.
Shares of NASDAQ:CCXI traded up $0.22 during trading on Friday, reaching $10.24. The stock had a trading volume of 99,513 shares, compared to its average volume of 276,900. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.69 and a quick ratio of 2.69. The firm has a market cap of $635.92 million, a PE ratio of 28.44 and a beta of 1.55. ChemoCentryx Inc has a fifty-two week low of $5.42 and a fifty-two week high of $15.08.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. ChemoCentryx had a net margin of 18.69% and a return on equity of 39.31%. The business had revenue of $15.02 million during the quarter, compared to analyst estimates of $16.88 million. As a group, sell-side analysts expect that ChemoCentryx Inc will post -0.86 earnings per share for the current fiscal year.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Read More: Diversification
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.